Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPATE vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Major depressive disorder,Generalized anxiety disorder,Panic disorder,Social anxiety disorder,Obsessive-compulsive disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Hypertension
50 mg orally once daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal half-life of 12-15 hours (range 10-18h) in adults; prolonged in renal impairment (up to 30h in severe cases).
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Hepatic primarily via CYP2C19, CYP2D6, CYP3A4, and CYP2C9; active metabolite desmethylsertraline.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Primarily renal excretion of unchanged drug (60-80%); biliary/fecal elimination accounts for 15-20%.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
95-98% bound, primarily to albumin and alpha-1-acid glycoprotein.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
0.5-0.7 L/kg (suggests moderate tissue penetration; primarily extracellular distribution).
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 70-80% (first-pass metabolism 20-30%; food reduces absorption by 10-15%).
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No dosage adjustment required for GFR ≥30 m L/min; GFR <30 m L/min: not recommended.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 25 mg once daily; Child-Pugh C: not recommended.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not approved for pediatric use.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No dosage adjustment required; monitor renal function.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None
Suicidality risk in pediatric/young adult patients,Serotonin syndrome risk with concomitant serotonergic drugs,Bleeding risk with anticoagulants/antiplatelets,Activation of mania/hypomania,Seizure risk in patients with epilepsy,Angle-closure glaucoma risk,Hyponatremia risk in elderly/dehydrated patients,Discontinuation syndrome with abrupt cessation
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Concurrent MAOIs (including linezolid and methylene blue),Concurrent pimozide,Known hypersensitivity to sertraline
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Grapefruit and grapefruit juice may increase sertraline levels; avoid consumption.,Alcohol: Avoid or limit intake to prevent worsening of side effects and reduced drug efficacy.,St. John's Wort: Concomitant use increases risk of serotonin syndrome; avoid.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
SERPATE is contraindicated in pregnancy. First trimester exposure carries risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. For all trimesters, increased risk of spontaneous abortion and stillbirth has been reported.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
SERPATE is excreted into human breast milk. Milk-to-plasma ratio is approximately 2:1. Breastfeeding is not recommended during therapy due to potential for severe adverse reactions in the nursing infant. Advise women to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Due to significant pharmacokinetic changes in pregnancy, including increased clearance (by 50%) and expanded volume of distribution, the dose of SERPATE should be increased by 30% during the second and third trimesters. Monitor therapeutic drug levels to maintain trough concentrations within the target range. Postpartum, reduce to prepregnancy dose within 48 hours to avoid toxicity.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
SERPATE is a brand name for sertraline, a selective serotonin reuptake inhibitor (SSRI). Initiate at 25-50 mg daily, titrate up to 200 mg maximum. Monitor for serotonin syndrome, especially with other serotonergic drugs. Abrupt discontinuation may cause withdrawal symptoms; taper gradually. Use with caution in bipolar disorder due to risk of manic switching. Adjusted dosing may be needed in hepatic impairment; no adjustment for renal impairment. May increase risk of bleeding, especially with NSAIDs or anticoagulants. Monitor for hyponatremia in elderly or volume-depleted patients.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take sertraline exactly as prescribed, usually once daily with or without food.,It may take 2-4 weeks to feel full benefit; do not stop abruptly without consulting your doctor.,Common side effects include nausea, diarrhea, dry mouth, dizziness, and trouble sleeping; these often improve over time.,Contact your doctor immediately if you experience signs of serotonin syndrome (e.g., agitation, hallucinations, fever, fast heart rate, muscle stiffness, twitching, coordination problems) or bleeding (e.g., unusual bruising, nosebleeds).,Avoid alcohol, as it can worsen side effects and reduce drug effectiveness.,Inform all healthcare providers that you are taking sertraline, especially before surgery or any procedure.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks and benefits with your doctor.,Do not take with MAO inhibitors (e.g., linezolid, methylene blue) or within 14 days of stopping them.,Store at room temperature away from moisture and heat.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPATE vs ALDORIL D30, answered by our medical review team.
SERPATE is a Antihypertensive that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPATE and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPATE is: 50 mg orally once daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPATE and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPATE is classified as Category C. SERPATE is contraindicated in pregnancy. First trimester exposure carries risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second . ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.